Nymox Pharmaceutical (NYMX) Reports Positive Results From Combined Statistical Analysis of Long Term Follow-Up Studies of BPH Drug  
7/31/2012 9:17:52 AM

HASBROUCK HEIGHTS, N.J., July 31, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported positive results from a new study of long-term treatment outcomes for men who had received a single injection of NX-1207 2.5 mg for treatment for their benign prostatic hyperplasia (BPH). The study analysis found that a statistically significant greater number of men who had received NX-1207 2.5 mg reported positive treatment outcomes as compared to men who had received a placebo. The study involved the latest available blinded follow-up study data (an average of 57 months post-injection) from the completed clinical trials for these treatment groups. A positive treatment outcome was seen if the patient was not using other BPH medications and no surgical treatment (including MIST) for BPH was reported at any time during the post-injection follow-up period.